218 related articles for article (PubMed ID: 24551307)
21. Molecular identification of a TPR-FGFR1 fusion transcript in an adult with myeloproliferative neoplasm, T-lymphoblastic lymphoma, and a t(1;8)(q25;p11.2).
Kim SY; Kim JE; Park S; Kim HK
Cancer Genet; 2014 Jun; 207(6):258-62. PubMed ID: 25037443
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Li F; Zhai YP; Tang YM; Wang LP; Wan PJ
Genes Chromosomes Cancer; 2012 Sep; 51(9):890-7. PubMed ID: 22619110
[TBL] [Abstract][Full Text] [Related]
23. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
24. FGFR1-associated myeloid neoplasm with increased mast cells.
Roth CG; Agha M
Br J Haematol; 2017 Apr; 177(2):172. PubMed ID: 28146284
[No Abstract] [Full Text] [Related]
25. [8p11 myeloproliferative syndrome].
Li F; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1073-7. PubMed ID: 23998615
[TBL] [Abstract][Full Text] [Related]
26. Myeloid/lymphoid neoplasm with a novel cryptic
Yang T; Mahmood N; Goldberg B; Cevallos J; Hsu P; Kolitz J; Cohen N; Zhang X
Leuk Lymphoma; 2023 Dec; 64(14):2338-2342. PubMed ID: 37791611
[No Abstract] [Full Text] [Related]
27. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).
Guasch G; Popovici C; Mugneret F; Chaffanet M; Pontarotti P; Birnbaum D; Pébusque MJ
Blood; 2003 Jan; 101(1):286-8. PubMed ID: 12393597
[TBL] [Abstract][Full Text] [Related]
28. [8p11 myeloproliferative syndrome with CEP110-FGFR1 fusion in a patient].
Chao H; Chen S; Zhou M; Lu X; Zhang X; Pan J; Wu C; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Oct; 32(5):679-82. PubMed ID: 26418991
[TBL] [Abstract][Full Text] [Related]
29. [Characteristic of 8p11 Myeloproliferative Syndrome with Rare Phenotype].
Xue S; Xu HX; Zhang YP; Liu FH; Lu YY; Li F; Wang YP; Wang CC; Jia XP; Wang JB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):181-187. PubMed ID: 33554816
[TBL] [Abstract][Full Text] [Related]
30. Acute leukemia with cytogenetically cryptic FGFR1 rearrangement and lineage switch during therapy: A case report and literature review.
McKeague SJ; O'Rourke K; Fanning S; Joy C; Throp D; Adams R; Harvey Y; Keng TB
Am J Clin Pathol; 2024 Feb; 161(2):197-205. PubMed ID: 37855739
[TBL] [Abstract][Full Text] [Related]
31. Precursor T-Lymphoblastic Lymphoma Associated with t(8;9)(p11.2;q33): A Case Report and Review of the Literature.
Lv H; Hu S; Lu J; Zhai Q; Zhai Z; Du Z; Sun Y; Li J; He H; Wang Y
Acta Haematol; 2018; 139(3):176-182. PubMed ID: 29614500
[TBL] [Abstract][Full Text] [Related]
32. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
[TBL] [Abstract][Full Text] [Related]
33. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
Landberg N; Dreimane A; Rissler M; Billström R; Ågerstam H
Eur J Haematol; 2017 Nov; 99(5):442-448. PubMed ID: 28881484
[TBL] [Abstract][Full Text] [Related]
34. Myeloid/lymphoid neoplasm with
Chen D; Liu G; Lewis MR; Li X; Ulrickson M; Nath R; Chen W
Leuk Res Rep; 2023; 19():100370. PubMed ID: 37275466
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.
Sotlar K; Cerny-Reiterer S; Petat-Dutter K; Hessel H; Berezowska S; Müllauer L; Valent P; Horny HP
Mod Pathol; 2011 Apr; 24(4):585-95. PubMed ID: 21186345
[TBL] [Abstract][Full Text] [Related]
36. A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review.
Washburn E; Bayerl MG; Ketterling RP; Malysz J
Cancer Genet; 2021 Nov; 258-259():69-73. PubMed ID: 34551378
[TBL] [Abstract][Full Text] [Related]
37. Submicroscopic deletion of FGFR1 gene is recurrently detected in myeloid and lymphoid neoplasms associated with ZMYM2-FGFR1 rearrangements: a case study.
Yang JJ; Park TS; Choi JR; Park SJ; Cho SY; Jun KR; Kim HR; Lee JN; Oh SH; Lee S; Kim B; Marschalek R; Meyer C
Acta Haematol; 2012; 127(2):119-23. PubMed ID: 22236811
[No Abstract] [Full Text] [Related]
38. [Clinical Significance of FGFR1 Gene Abnormalities in Blood Tumors].
Zhang CL; Tang GS; Guo MQ; Cheng H; Liu MD; Yang JM; Gong SL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):983-988. PubMed ID: 32552969
[TBL] [Abstract][Full Text] [Related]
39. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
Mozziconacci MJ; Carbuccia N; Prebet T; Charbonnier A; Murati A; Vey N; Chaffanet M; Birnbaum D
Leuk Res; 2008 Aug; 32(8):1304-8. PubMed ID: 18096225
[TBL] [Abstract][Full Text] [Related]
40. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
